University of Pennsylvania Addiction Treatment Research Center
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01524627
Varenicline is the best smoking cessation agent to date; however it is only effective in a subgroup of smokers and is associated with undesirable side effects in other subgroups. To understand the underlying pharmaco-heterogeneity, the proposed project will use perfusion functional magnetic resonance imaging and a functional candidate gene association approach using brain, behavioral, and clinical endpoints in a placebo-controlled study of chronic varenicline administration in smokers. Brain and behavioral responses to smoking cues will be will be significantly greater in 9/10-repeats compared to 10/10-repeats. DAT 9/10-repeat smokers receiving varenicline will have better treatment outcome compared to 10/10-repeats. For the purposes of the clinical trial portion of the study, the change from cigarettes per day at Baseline to the last day of treatment will be reported.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Other names: Chantix
Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Other names: Sugar Pill
Time frame: last week of treatment (1-8 weeks)
Cigarettes per day at Baseline versus 8 weeks of treatment, placebo-controlled
University of Pennsylvania
Other
Characterizing a Cue-vulnerable Pharmaco-responsive Endophenotype in Smokers
Acronym: VSMK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01867411
Behavior, Chemically-Induced Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT03968900
Behavior, Chemically-Induced Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT05206435
Behavior, Chemically-Induced Disorders
Providence, Rhode Island, United States
View Trial DetailsNCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial Details